MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.49
+0.24
+0.85%
Opening 12:28 06/22 EDT
OPEN
28.40
PREV CLOSE
28.25
HIGH
28.92
LOW
27.94
VOLUME
104.03K
TURNOVER
--
52 WEEK HIGH
33.24
52 WEEK LOW
9.59
MARKET CAP
1.13B
P/E (TTM)
-15.5556
1D
5D
1M
3M
1Y
5Y
Celldex Therapeutics Stock Is Believed To Be Significantly Overvalued
GuruFocus News · 2d ago
Bionano Genomics to join Russel 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen
Seekingalpha · 06/14 20:55
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company's Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented in a poster session as pa...
GlobeNewswire · 06/04 13:01
BRIEF-Celldex Announces Acceptance Of Abstract For Cdx-0159 Phase 1B Results In Inducible Urticaria For Late-Breaking Presentation At The European Academy Of Allergy And Clinical Immunology (Eaaci) Annual Congress 2021
reuters.com · 06/01 13:06
Celldex Therapeutics To Present Abstract From Phase 1B Study Of CDX-0159 At European Academy Of Allergy And Clinical Immunology Annual Congress 2021 Jul. 10
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic
Benzinga · 06/01 11:33
Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism (SD), the two most commo...
GlobeNewswire · 06/01 11:31
Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30 p.m. ET.
GlobeNewswire · 05/26 20:01
Redmile Group, LLC Buys Jazz Pharmaceuticals PLC, Seagen Inc, Medtronic PLC, Sells AbbVie Inc, ...
GuruFocus News · 05/18 20:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLDX. Analyze the recent business situations of Celldex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLDX stock price target is 34.67 with a high estimate of 36.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 159
Institutional Holdings: 48.16M
% Owned: 121.56%
Shares Outstanding: 39.61M
TypeInstitutionsShares
Increased
38
5.75M
New
19
1.23M
Decreased
37
6.84M
Sold Out
33
2.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Karen Shoos
Chief Executive Officer/President/Director
Anthony Marucci
Chief Financial Officer/Senior Vice President/Secretary
Sam Martin
Executive Vice President/Chief Scientific Officer
Tibor Keler
Senior Vice President/General Counsel
Freddy Jimenez
Senior Vice President/IR Contact Officer
Sarah Cavanaugh
Senior Vice President
Elizabeth Crowley
Senior Vice President
Margo Heath-Chiozzi
Senior Vice President
Ronald Pepin
Senior Vice President
Richard Wright
Senior Vice President
Diane Young
Independent Director
Keith Brownlie
Independent Director
Herbert Conrad
Independent Director
James Marino
Independent Director
Harry Penner
No Data
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.